Related Experiment Videos
The growing healthcare burden of CHF
1Department of Medical Economics, University Hospital, Zurich, CH-8091, Switzerland. thomas.szucs@vdi.usz.ch
Insights
Congestive heart failure (CHF) is a growing healthcare cost, driven by an aging population and better management of other conditions. Reducing disease severity and hospitalizations is key to lowering the economic burden of CHF.
Area of Science:
- Cardiology
- Health Economics
Background:
- Congestive heart failure (CHF) presents a significant economic challenge globally.
- Increasing CHF incidence is linked to an aging population and improved survival rates from conditions like myocardial infarction.
- A disproportionate amount of healthcare resources are consumed by patients with advanced CHF (NYHA classes III-IV).
Purpose of the Study:
- To analyze the economic burden of congestive heart failure (CHF).
- To identify key factors driving the increasing incidence and cost of CHF.
- To evaluate the impact of disease severity and hospitalization on overall CHF healthcare expenditure.
Main Methods:
- Analysis of healthcare resource utilization in congestive heart failure (CHF) management.
- Examination of demographic shifts and advancements in cardiovascular event management.
- Assessment of cost distribution across different patient severity classes (NYHA III-IV) and hospitalisation rates.
Main Results:
- Hospitalization accounts for a substantial portion (60-75%) of total CHF costs.
- Patients in NYHA classes III or IV utilize approximately 90% of CHF management resources.
- Improved survival from other conditions contributes to a higher prevalence of CHF.
Conclusions:
- Management strategies focusing on reducing disease severity are crucial for mitigating CHF's economic impact.
- Targeting interventions to decrease hospitalisation rates can lead to significant healthcare cost savings for CHF.
- Effective CHF management requires a dual approach addressing both patient condition and healthcare resource utilization.
Abstract:
Despite advances in treatment, congestive heart failure (CHF) remains a major burden on healthcare budgets throughout the western world. Two main factors in the increasing incidence of CHF are the shift in the age distribution of the population and, paradoxically, an improvement in the management of other conditions, such as myocardial infarction. This increases the number of patients surviving acute cardiovascular events who proceed to develop CHF. Certain sub-populations of patients consume most of the healthcare resources devoted to CHF management, with some 90% of resources utilised by patients in NYHA classes III or IV, and hospitalisation accounting for 60 to 75% of overall costs. Management strategies aimed at reducing both disease severity and the need for hospitalisation are therefore likely to be most effective in reducing the economic burden of CHF on healthcare systems.